Molecular Biology of the Cell by Bruce Alberts, Alexander Johnson, Julian Lewis, David Morgan, Martin Raff, Keith Roberts, Peter Walter by by Bruce Alberts, Alexander Johnson, Julian Lewis, David Morg

1144 Chapter 20: Cancer
Cancer-Critical Genes: How They Are Found and
What They Do
Berdasco M & Esteller M (2010) Aberrant epigenetic landscape in
cancer: how cellular identity goes awry. Dev. Cell 19, 698–711.
Brognard J & Hunter T (2011) Protein kinase signaling networks in
cancer. Curr. Opin. Genet. Dev. 21, 4–11.
Eilers M & Eisenman R (2008) Myc’s broad reach. Genes Dev.
22, 2755–2766.
Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human
disease. Nature 447, 433–440.
Garraway LA & Lander ES (2013) Lessons from the cancer genome.
Cell 153, 17–37.
Greaves M & Maley CC (2012) Clonal evolution in cancer. Nature
481, 306–313.
Junttila MR & Evan GI (2009) p53—a Jack of all trades but master of
none. Nat. Rev. Cancer 9, 821–829.
Levine AJ (2009) The common mechanisms of transformation by the
small DNA tumor viruses: the inactivation of tumor suppressor gene
products: p53. Virology 384, 285–293.
Lu P, Weaver VM & Werb Z (2012) The extracellular matrix: a dynamic
niche in cancer progression. J. Cell Biol. 196, 395–406.
Mitelman F, Johansson B & Mertens F (2007) The impact of
translocations and gene fusions on cancer causation. Nat. Rev.
Cancer 7, 233–245.
Negrini S, Gorgoulis VG & Halazonetis TD (2010) Genomic instability—
an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11,
220–228.
Nguyen DX, Bos PD & Massagué J (2009) Metastasis: from
dissemination to organ-specific colonization. Nat. Rev. Cancer
9, 274–284.
Radtke F & Clevers H (2005) Self-renewal and cancer of the gut: two
sides of a coin. Science 307, 1904–1909.
Rowley JD (2001) Chromosome translocations: dangerous liaisons
revisited. Nat. Rev. Cancer 1, 245–250.
Shaw RJ & Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls
tumour cell growth. Nature 441, 424–430.
Suvà ML, Riggi N & Bernstein BE (2013) Epigenetic reprogramming in
cancer. Science 339, 1567–1570.
Weinberg RA (1995) The retinoblastoma protein and cell cycle control.
Cell 81, 323–330.
Cancer Prevention and Treatment: Present and
Future
Al-Hajj M, Becker MW, Wicha M et al. (2004) Therapeutic implications
of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43–47.
Ames B, Durston WE, Yamasaki E & Lee FD (1973) Carcinogens are
mutagens: a simple test system combining liver homogenates for
activation and bacteria for detection. Proc. Natl Acad. Sci. USA
70, 2281–2285.
Bozic I, Reiter JG, Allen B et al. (2013) Evolutionary dynamics of cancer
in response to targeted combination therapy. eLife 2, e00747.
Doll R & Peto R (1981) The causes of cancer: quantitative estimates of
avoidable risks of cancer in the United States today. J. Natl Cancer
Inst. 66, 1191–1308.
Druker BJ & Lydon NB (2000) Lessons learned from the development
of an Abl tyrosine kinase inhibitor for chronic myelogenous
leukemia. J. Clin. Invest. 105, 3–7.
Huang P & Oliff A (2001) Signaling pathways in apoptosis as potential
targets for cancer therapy. Trends Cell Biol. 11, 343–348.
Jain RK (2005) Normalization of tumor vasculature: an emerging
concept in antiangiogenic therapy. Science 307, 58–62.
Jonkers J & Berns A (2004) Oncogene addiction: sometimes a
temporary slavery. Cancer Cell 6, 535–538.
Kalos M & June CH (2013) Adoptive T cell transfer for cancer
immunotherapy in the era of synthetic biology. Immunity 39, 49–60.
Loeb LA (2011) Human cancers express mutator phenotypes: origin,
consequences and targeting. Nat. Rev. Cancer 11, 450–457.
Lord CJ & Ashworth A (2012) The DNA damage response and cancer
therapy. Nature 481, 287–294.
Pardoll DM (2012) The blockade of immune checkpoints in cancer
immunotherapy. Nat. Rev. Cancer 12, 252–264.
Peto J (2001) Cancer epidemiology in the last century and the next
decade. Nature 411, 390–395.
Sawyers C (2004) Targeted cancer therapy. Nature 432, 294–297.
Schreiber RD, Old LJ & Smyth MJ (2011) Cancer immunoediting:
integrating immunity’s roles in cancer suppression and promotion.
Science 331, 1565–1570.
Sliwkowski MX & Mellman I (2013) Antibody therapeutics in cancer.
Science 341, 1192–1198.
Varmus H, Pao W, Politi K et al. (2005) Oncogenes come of age. Cold
Spring Harb. Symp. Quant. Biol. 70, 1–9.
Ward RJ & Dirks PB (2007) Cancer stem cells: at the headwaters of
tumor development. Annu. Rev. Pathol. 2, 175–189.